❤️

Houston Methodist- Cardiac Biomarkers Overview

Aug 30, 2025

Overview

This lecture covers advances in cardiac biomarkers, particularly natriuretic peptides and troponin, focusing on their roles in heart failure diagnosis, risk prediction, monitoring, and future directions for clinical practice and research.

Introduction to Cardiac Biomarkers

  • Cardiac biomarkers support but do not replace clinical judgment in cardiovascular disease management.
  • Natriuretic peptides and troponin are the main biomarkers used for heart failure and myocardial injury.
  • Biomarkers can detect what is not visible clinically or by imaging.

Natriuretic Peptides (NPs)

  • NPs are synthesized in response to myocardial stress, not just heart failure.
  • BNP and NT-proBNP are common NPs used for diagnosis and prognosis.
  • NPs are derived from precursor peptides; their fragments have different biological effects.
  • Neprilysin inhibitors (e.g., sacubitril/valsartan) affect NP levels but do not diminish their prognostic value.
  • Severe heart failure leads to more uncleaved proBNP, which is inactive and detected by both BNP and NT-proBNP assays.
  • Serial measurements of NPs help guide therapy, predict outcomes, and monitor cardiac remodeling.

Troponin

  • Troponin I and T are specific markers for myocardial injury, not just infarction.
  • High-sensitivity assays detect low levels even in the general population; elevated levels signal increased risk.
  • Troponin can be released due to myocardial stress without cell death, via exosomes.
  • Elevated or rising troponin levels in chronic disease indicate worse prognosis and ongoing stress.

Risk Stratification and Prevention

  • The new universal definition of heart failure includes abnormal NP or troponin levels (“Stage B” or pre-heart failure).
  • Adding biomarkers to traditional imaging doubles at-risk patient identification without sacrificing specificity.
  • Annual biomarker measurement is recommended for high-risk populations, including those with diabetes.
  • Age, sex, and comorbidities (CKD, obesity) influence NP interpretation; thresholds may need adjustment.

Biomarker Use in Clinical Practice

  • In acute heart failure, NP levels reflect volume overload and therapy response; a 30% reduction is a target.
  • Outpatient serial NP tracking is prognostically valuable; trends predict events and remodeling.
  • Home-based NP testing devices are emerging for remote monitoring and therapy adjustment.
  • NPs help guide diuretic discontinuation and identify patients needing closer follow-up or advanced workup.

Advanced and Future Biomarker Approaches

  • Proteomics (“omics”) enables discovery of new biomarkers (e.g., IGFBP7) and therapeutic targets.
  • Multi-marker panels and machine learning can improve diagnosis and risk prediction (e.g., for coronary disease).
  • Translation of biomarker discovery into clinical testing and therapies is slowed by regulatory and technological barriers.
  • Implementation of new biomarkers should focus on actionable changes, not just risk prediction.

Key Terms & Definitions

  • Natriuretic Peptides (NPs) — Hormones released by the heart in response to wall stress, used for diagnosing and managing heart failure.
  • Troponin — Cardiac-specific protein complex released during myocardial injury.
  • High-Sensitivity Troponin — Assay detecting very low troponin levels, identifying subtle myocardial injury.
  • ProBNP 108 — Uncleaved precursor of BNP; accumulation signals advanced heart failure.
  • Neprilysin Inhibitors — Drugs blocking NP degradation, used in heart failure treatment.
  • Proteomics — Large-scale study of proteins for biomarker discovery and disease understanding.

Action Items / Next Steps

  • For high-risk patients (e.g., diabetes, CKD), consider annual NP and troponin testing.
  • Adjust NP thresholds for obesity, age, and comorbidities as needed.
  • Monitor heart failure outpatients with serial NP (every 3 months or more frequently if unstable).
  • Stay informed about home-based NP testing and emerging multi-marker panels.

Certainly! Here is a comprehensive, in-depth summary and review of the entire lecture on cardiac biomarkers, focusing on natriuretic peptides and troponin, their clinical applications, biological insights, and future directions:

Comprehensive Summary and Review of Cardiac Biomarkers Lecture

1. Introduction and Context

  • The lecture was delivered by Dr. James Januzzi, a leading expert in cardiac biomarkers, with over 30 years of experience.
  • Focus: Evolution, current state, and future of cardiac biomarkers, especially natriuretic peptides (NPs) and troponin, primarily in heart failure (HF).
  • Emphasis on biomarkers as tools to support clinical judgment, not replace it.
  • Biomarkers reveal biological processes and disease states not visible by bedside exam or imaging.

2. Natriuretic Peptides (NPs)

Historical Background

  • 1960s: Eugene Braunwald speculated the heart as an endocrine organ releasing substances (initially CRP) to prognosticate HF.
  • 1984: Adolfo de Bold discovered atrial natriuretic factor (ANF) causing natriuresis and diuresis.
  • BNP (B-type natriuretic peptide) was later identified, initially in brain tissue but mainly produced in the myocardium.
  • NPs are highly conserved across species, originating from deep-water fish to regulate blood osmolarity.

Biology and Processing

  • NPs are synthesized in response to myocardial stress, not just heart failure.
  • Pre-proBNP (precursor) is synthesized, loses a signal peptide, yielding proBNP 108.
  • Unlike ANP stored in granules, BNP is synthesized de novo.
  • ProBNP 108 is cleaved by enzymes (corin, furin) into:
    • NT-proBNP (N-terminal fragment, inactive)
    • BNP (active peptide causing vasodilation, natriuresis, anti-fibrosis via cyclic GMP signaling)
  • BNP and ANP bind to natriuretic peptide receptor A (NPR-A), CNP binds NPR-B, and all are cleared by NPR-C.

Complexity of Circulating Peptides

  • BNP circulates as multiple fragments, not just intact peptide.
  • Different fragments have varying biological effects (natriuresis, vasodilation).
  • This complexity explains variable assay results and biological effects.
  • Neprilysin inhibitors (e.g., sacubitril/valsartan) block degradation of NPs, increasing BNP levels but not NT-proBNP.
  • Clinical trials (PARADIGM-HF) showed BNP rises ~19% after neprilysin inhibition but remains prognostic.

Uncleaved proBNP 108 and Advanced HF

  • In advanced HF, more uncleaved proBNP 108 is released.
  • This peptide is inactive (does not stimulate cyclic GMP).
  • Both BNP and NT-proBNP assays cross-react with proBNP 108, explaining why both rise similarly.
  • Rising NP levels despite therapy may reflect increased proBNP 108, indicating worsening myocardial stress.
  • Therapeutic opportunities exist to enhance cleavage or mimic NP receptor activation (e.g., monoclonal antibodies targeting NPR-A).

3. Troponin

Discovery and Biology

  • Troponin I and T are cardiac-specific proteins involved in muscle contraction.
  • Developed as biomarkers for myocardial injury (not just infarction).
  • High-sensitivity troponin assays detect very low levels in most healthy individuals.
  • Troponin release reflects myocardial injury or stress, not necessarily cell death.

Mechanisms of Troponin Release

  • Two pools in cardiomyocytes:
    • Cytosolic pool (~3-4% of total troponin)
    • Contractile apparatus pool (majority)
  • Injury causes rapid release of cytosolic troponin (detectable within 1 hour).
  • Later, contractile apparatus degradation causes prolonged elevation.
  • Troponin can also be released via exosomes without cell death, as a form of cell-to-cell communication.
  • Exosomal troponin release varies by disease state (higher in HF, CKD).

Clinical Implications

  • Elevated troponin in the general population signals subclinical myocardial injury and increased risk.
  • High-sensitivity assays improve detection and risk stratification.
  • Troponin elevation is not synonymous with myocardial infarction (MI); must consider supply-demand mismatch (type 2 MI) and other causes.
  • Misclassification of type 2 MI is common; clinical context is critical.

4. Risk Stratification and Prevention Using Biomarkers

Universal Definition of Heart Failure (HF)

  • Introduced stages:
    • Stage A: At risk (e.g., hypertension, diabetes)
    • Stage B: Pre-HF (structural heart disease or abnormal biomarkers, no symptoms)
    • Stage C: Symptomatic HF
  • Adding abnormal NP or troponin to structural abnormalities doubles the number of patients identified as Stage B.
  • Biomarkers improve risk prediction without reducing specificity.
  • More women and individuals with social determinants of health (Hispanic, Black) are identified using biomarkers.
  • Elevated biomarkers in Stage B predict progression to symptomatic HF and cardiovascular death.

Biomarker Screening Recommendations

  • American Diabetes Association (ADA) recommends annual NP or high-sensitivity troponin testing in diabetes.
  • Biomarkers identify early molecular signals of HF risk.
  • Age, sex, obesity, and comorbidities affect biomarker interpretation.
  • Adjust thresholds accordingly (e.g., lower NP cutoffs in obesity).

5. Biomarker Use in Clinical Practice

Acute Heart Failure (AHF)

  • NP levels reflect volume overload and myocardial stress.
  • Serial NP measurements during hospitalization guide therapy.
  • A 30% reduction in NP is a target for adequate decongestion.
  • Pre-discharge NP levels predict 6-month outcomes.

Outpatient Monitoring

  • Serial NP measurements every 3 months (or more frequently if unstable) predict events and remodeling.
  • Trends in NP correlate with reverse cardiac remodeling and improved ejection fraction.
  • Rising NP levels precede clinical events by weeks to months.
  • Home-based NP testing devices (fingerstick, smartphone-connected) are emerging for remote monitoring and therapy titration.
  • NP levels guide decisions on diuretic discontinuation and intensity of follow-up.
  • Elevated NP despite therapy may indicate alternative diagnoses (e.g., cardiac amyloidosis, thyroid disease).

6. Troponin in Heart Failure

  • Troponin is a powerful predictor of adverse outcomes in both reduced and preserved EF HF.
  • Troponin and NP together provide additive prognostic information.
  • Troponin changes over time reflect ongoing myocardial injury/stress.
  • Mitigating both NP and troponin levels correlates with better cardiac remodeling.

7. Advanced Biomarker Approaches and Future Directions

Proteomics and Omics Technologies

  • Proteomics enables large-scale protein profiling from small blood samples.
  • Technologies include aptamer-based assays and proximity extension assays.
  • These allow discovery of novel biomarkers and pathways.

Examples of Novel Biomarkers

  • IGF Binding Protein 7 (IGFBP7):
    • Identified via proteomics as a marker of cardiac remodeling and acute kidney injury risk.
    • Associated with cellular senescence and fibrosis.
    • Targeted therapeutically in animal models to prevent HF onset.

Multi-marker Panels and Machine Learning

  • Combining multiple proteins and clinical variables can predict obstructive coronary artery disease with high accuracy (~90% AUC).
  • Such panels may outperform traditional imaging or single markers.

Challenges in Translation

  • Rapid discovery outpaces development of clinical assays.
  • Regulatory hurdles slow approval of new tests.
  • Ambiguity around lab-developed tests (LDTs) and FDA oversight.
  • Need for integration of biomarker discovery with therapeutic development (implementation science).

8. Practical Considerations and Q&A Highlights

Biomarker Testing Frequency

  • Stable HF patients: NP testing every 3 months.
  • Unstable or titrating therapy: testing every 1-2 weeks may be useful.
  • Home-based testing may facilitate more frequent monitoring.

Interpretation in Obesity

  • Obesity suppresses NP gene expression, leading to ~10-30% lower NP levels.
  • Troponin and other markers (ST2, IGFBP7) are less affected by obesity.
  • Adjust NP thresholds downward in obese patients.

Prevention Clinics and Screening

  • Heart failure prevention clinics are ideal but not widely available.
  • Early detection via biomarkers can identify high-risk patients for aggressive management.
  • ADA guidelines support biomarker use in diabetes for HF risk stratification.

Type 2 Myocardial Infarction (MI) and Troponin

  • Type 2 MI diagnosis is challenging; many cases are misclassified.
  • Troponin elevation reflects myocardial stress/injury, not always infarction.
  • Clinical context and additional testing are essential.

Implementation Science

  • Biomarker discovery must be linked to actionable therapies.
  • Oncology provides a model for personalized medicine.
  • Cardiology needs to develop targeted therapies based on biomarker pathways.
  • Editorials call for higher standards in biomarker research focusing on clinical utility.

9. Summary and Conclusions

  • Cardiac biomarkers have evolved from diagnostic tools for acute HF and MI to powerful prognostic and preventive tools.
  • Natriuretic peptides and troponin provide complementary information about myocardial stress and injury.
  • Biomarkers identify early disease, guide therapy, and predict outcomes.
  • Emerging technologies (proteomics, multi-marker panels) promise deeper insights and personalized care.
  • Challenges remain in translating discoveries into clinical practice due to regulatory and technological barriers.
  • The future of cardiac biomarkers lies in prevention, precision medicine, and integration with novel therapeutics.

Key Takeaways for Clinical Practice

  • Use NP and troponin to support clinical judgment in HF diagnosis and management.
  • Recognize that biomarkers detect myocardial stress and injury, not just overt HF or MI.
  • Incorporate serial biomarker measurements to monitor therapy response and predict events.
  • Adjust interpretation for age, sex, obesity, and comorbidities.
  • Consider annual biomarker testing in high-risk populations (e.g., diabetes).
  • Stay informed about home-based testing and multi-marker panels.
  • Advocate for biomarker-guided prevention clinics and personalized therapies.

If you want, I can also help you create a detailed study guide or outline based on this summary! Just let me know.

Full transcript